Full-Time

Director CX Data Enablement & Platforms Technical Suite Lead

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$188k - $282k/yr

Pennsylvania, USA

Remote

Remote within Pennsylvania, with 10–20% travel required.

Bachelor's, Master's

Category
Engineering Management (1)
Required Skills
Agile
Data Engineering
REST APIs

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in computer science, engineering, information systems, or a related technical field is required.
  • 10+ years of experience after a bachelor's degree, or 8+ years of experience after a master's degree, in data engineering, technical architecture, or enterprise platform delivery management is required.
  • At least 3 years of experience as a Tech Lead, Technical Program Manager, Engineering Manager, or in another role involving management of a developer team is required.
  • 6–8 years of experience leading people, including managing and developing high-performing teams and driving accountability across functions, is required.
  • Demonstrated experience designing and delivering enterprise-scale digital platforms, including enterprise data platforms supporting master data, reference data, and analytics-ready datasets, is required.
  • Experience guiding technical architecture within complex, matrixed, global organizations is required.
  • Experience using Agile and Product Operating Model principles to drive alignment, autonomy, and outcome-focused delivery is required.
  • The candidate must be able to lead and mentor engineering teams and technical leaders.
  • The candidate must have a deep understanding of enterprise data and platform architecture, cloud-based data services, and modern engineering frameworks for scalable, reusable data solutions.
  • The candidate must have experience designing and configuring secure, reliable, and compliant enterprise-scale data platforms within pharmaceutical and healthcare industries.
  • The candidate must have strong knowledge of data integration patterns, application programming interfaces, and data product architectures supporting governed data flows.
  • The candidate must have experience designing and evolving enterprise data enablement solutions, including shared data services, data mastering, and analytics-ready data products.
  • The candidate must have experience evolving master data management platforms as enterprise products, including roadmap evolution, consumer onboarding, and alignment with domain owners and vendor partners.
  • The candidate must understand identity resolution strategies, including survivorship rules and cross-domain linkage trade-offs, and have experience embedding consent and preference management into mastering workflows.
  • The candidate must be able to lead data stewardship operations end to end, including exception management, governance adherence, and consistent execution across domains.
  • The candidate must have experience working within Agile product development teams and product operating models.
  • The candidate must understand security, privacy, and regulatory requirements for enterprise data management, access controls, and compliant data usage.
  • The candidate must demonstrate technical program leadership across multi-team and multi-vendor data initiatives, coordinating dependencies and delivery.
  • The candidate must be able to design and oversee compliant technical operations for data platforms, including reliability, support, business continuity, and managed service models.
  • The candidate must have experience leading and developing a high-performing team, including resource planning, performance management, and talent development.
  • The candidate must be able to work through cross-functional matrix collaboration, customer journey understanding, outside-in thinking, critical thinking, business acumen, and trade-off decisions involving competing resources, priorities, and outcomes.
Responsibilities
  • Set and drive the technical direction for the Data Enablement & Platforms team within Customer Experience Operations, with accountability for platform scalability, reliability, and compliant workflows across the enterprise.
  • Collaborate with the Data Enablement & Platforms CX Lead to create value-focused roadmaps for launching and enhancing technical capabilities.
  • Own budget and resource allocation, making investment decisions across capabilities and teams.
  • Translate product roadmaps into scalable technology architectures and development plans while assessing feasibility, constraints, dependencies, and risks.
  • Ensure technical and product decisions support regulated content governance and align with security policies, data controls, and medical, legal, and regulatory processes.
  • Lead and develop Technical Leads responsible for centralized data mastering, data stewardship, and standardized customer, payer, and patient data products.
  • Partner with leadership on workforce planning, capability development, and evolution of the operating model.
  • Manage vendor partners, ensuring accountability, quality delivery, and alignment to objectives.
  • Act as the primary technical point of accountability for data master domains and partner with enterprise capability leads, architects, security, and data teams.
  • Coordinate roadmap dependencies, integrations, and architectural decisions across data master and management platforms and downstream systems.
  • Represent the technical architecture, platforms, and delivery considerations of the Data Enablement & Platforms team in domain, cross-team, and enterprise capability forums.
  • Lead resolution of cross-team issues affecting Data Enablement & Platforms performance or adoption.
  • Collaborate with CX Data Technical Leads and Enterprise Data and Artificial Intelligence Global Capability Owners to align shared data infrastructure, integration standards, and artificial intelligence and machine learning enablement.
  • Lead a team that includes technical owners, development teams, and vendor partners.
  • Drive performance, grow individuals, and create belonging as a people manager.
Desired Qualifications
  • An advanced degree in computer science, engineering, or a related field is preferred.
  • Experience in pharmaceutical or healthcare industries is preferred.
  • Experience partnering closely with product leadership in a product-based operating model is preferred.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics, is preferred.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.